SCHEMBL990527

SCHEMBL990527

COC(=O)C1(O)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374351 0.95 NPSR1 (0.52)
SCHEMBL7420059 0.92 NPSR1 (0.50)
SCHEMBL758201 0.92 NPSR1 (0.50)
SCHEMBL390361 0.89
SCHEMBL34476145 0.85 NPSR1 (0.37)
SCHEMBL2077252 0.81 NPSR1 (0.37)
Hydrochloric Acid SCHEMBL2077250 0.80 NPSR1 (0.36)
SCHEMBL15125365 0.78 CYP3A4 (0.42)
SCHEMBL854175 0.78 KDM4E (0.41)
SCHEMBL17027474 0.78 NPSR1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2025-12-25 US disclosed
EP-4490159-A1 TRICYCLIC HETEROCYCLE COMPOUNDS AS IAP ANTAGONISTS Ascentage Pharma (Suzhou) Co., Ltd. (CN) 2025-01-15 EP disclosed
EP-3691638-B1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS INC (US) 2024-12-11 EP disclosed
US-20240139158-A1 METHODS OF TREATING PULMONARY DISEASES AND DISORDERS PROTEOSTASIS THERAPEUTICS INC (US) 2024-05-02 US disclosed
CN-117580592-A Compounds for targeting bruton's tyrosine kinase degradation 渤健马萨诸塞州股份有限公司 2024-02-20 CN disclosed
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 US disclosed
US-20230365558-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-11-16 US disclosed
WO-2023169569-A1 TRICYCLIC HETEROCYCLE COMPOUNDS AS IAP ANTAGONISTS ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2023-09-14 WO disclosed
CN-116731016-A Tricyclic heterocyclic compounds as IAP antagonists 苏州亚盛药业有限公司 2023-09-12 CN disclosed
CN-116583509-A Compounds and methods for treating cancer 上海睿跃生物科技有限公司 2023-08-11 CN disclosed
US-20030060474-A1 Platelet adenosine diphosphate receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2003-03-27 US disclosed
EP-0929547-B1 BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID OR CYCL IC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS SCHERING AG (DE) 2002-11-27 EP disclosed
US-6265404-B1 FACTOR X INHIBITOR BERLEX LABORATORIES, INC. 2001-07-24 US disclosed
US-6232325-B1 THROMBOSIS THERAPY BERLEX LABORATORIES, INC. 2001-05-15 US disclosed
US-6177473-B1 FACTOR X INHIBITOR BERLEX LABORATORIES, INC. 2001-01-23 US disclosed
US-6008234-A TREATING A HUMAN HAVING A DISEASE-STATE CHARACTERIZED BY THROMBOTIC ACTIVITY, INHIBITING HUMAN BLOOD COAGULATION FACTOR XA BERLEX LABORATORIES, INC. (US) 1999-12-28 US disclosed
EP-0929547-A1 BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID OR CYCL IC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS SCHERING AKTIENGESELLSCHAFT (DE) 1999-07-21 EP disclosed
WO-1998011094-A1 BENZAMIDINE DERIVATIVES SUBSTITUTED BY CYCLIC AMINO ACID OR CYCL IC HYDROXY ACID DERIVATIVES AND THEIR USE AS ANTI-COAGULANTS SCHERING AKTIENGESELLSCHAFT (DE) 1998-03-19 WO disclosed
US-4291046-A AMIDATION BAYER AKTIENGESELLSCHAFT (DE) 1981-09-22 US disclosed
US-4200643-A Combating fungi with spiro derivatives of 3-(3,5-dihalogenophenyl)-oxazolidine-2,4-diones BAYER AKTIENGESELLSCHAFT (DE) 1980-04-29 US disclosed